This inventor holds 1 USPTO granted patent. Top assignee: Kowa Company Limited. Active years: 2014.
Company Filing History:
Years Active: 2014
Title: Ken Uesugi: Innovator in Hepatocellular Carcinoma Treatment
Introduction: Ken Uesugi is a notable inventor based in Musashino, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the prevention and treatment of hepatocellular carcinoma. His innovative approach combines various compounds to create effective medicinal agents.
Latest Patents: Uesugi holds a patent for a medicinal agent aimed at preventing and treating hepatocellular carcinoma. The patent describes a pharmaceutical agent that includes an acyclic retinoid, a salt thereof, or a solvate of any of these, combined with a branched-chain amino acid, a salt thereof, or a solvate of any of these. This invention represents a promising advancement in cancer treatment.
Career Highlights: Throughout his career, Ken Uesugi has been associated with Kowa Company Limited, where he has focused on developing innovative pharmaceutical solutions. His work has garnered attention for its potential impact on cancer therapy.
Collaborations: Uesugi has collaborated with notable colleagues, including Kazuhide Shimada and Tetsuro Sano. These partnerships have contributed to the advancement of research and development in the pharmaceutical field.
Conclusion: Ken Uesugi's contributions to the treatment of hepatocellular carcinoma highlight his role as an influential inventor in the pharmaceutical industry. His innovative approaches continue to pave the way for advancements in cancer treatment.